13F Holdings
中文EN

DERM Journey Medical Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1867066 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.0%
TTM net income YoY41.1%
TTM EPS YoY48.6%
Revenue 3-yr CAGR-4.5%
Net income 3-yr CAGR—

Margins

Gross margin65.9%
Operating margin-2.9%
Net margin-7.3%
FCF margin—
EBITDA margin—

Returns

ROE-17.6%
ROA-5.4%
ROIC (approx.)-5.2%
Asset turnover0.74x

Leverage & solvency

Liabilities / assets68.9%
Debt / equity0.79x
Current ratio1.48x
Interest coverage-0.55x

Cash quality & payout

Operating cash flow / net income1.67x
Accruals ratio3.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$61.86M$56.13M$79.18M$73.67M$63.13M
Cost of revenue$20.92M$20.88M$22.89M$30.77M$32.08M
Gross profit$40.93M$35.26M$56.29M$42.89M$31.05M
R&D expense$480,000$9.86M$7.54M$10.94M$2.74M
SG&A expense$44.37M$40.20M$43.91M$59.47M$39.83M
Operating income-$8.17M-$13.68M-$2.07M-$27.52M-$34.88M
Interest expense$3.70M$2.70M$1.70M$2.02M$7.03M
Pretax income-$11.37M-$14.61M-$3.63M-$29.57M-$42.36M
Income tax$60,000$61,000$221,000$63,000$1.63M
Net income-$11.43M-$14.67M-$3.85M-$29.63M-$43.99M
EBITDA————-$34.88M
EPS (basic)-0.47-0.72-0.21-1.69-4.32
EPS (diluted)-0.47-0.72-0.21-1.69-4.32
Weighted avg. shares (diluted)24.50M20.43M18.23M17.53M10.19M
Balance sheet
Cash & equivalents$24.09M$20.30M$27.44M$32.00M$49.08M
Receivables$29.78M$10.23M$15.22M$28.21M$23.11M
Inventory$9.62M$14.43M$10.21M$14.16M$9.86M
Current assets$66.87M$48.18M$56.45M$77.68M$84.49M
Intangibles$27.61M$31.86M$20.29M$27.20M$12.55M
Total assets$94.59M$80.24M$76.85M$105.16M$97.28M
Current liabilities$37.44M$35.17M$41.87M$66.83M$51.61M
Long-term debt$25.28M$24.88M$14.62M$19.83M—
Total debt$25.28M$24.88M$14.62M$19.83M—
Total liabilities$62.74M$60.17M$56.50M$88.18M$55.24M
Shareholders' equity$31.85M$20.07M$20.35M$16.98M$42.04M
Net debt$1.19M$4.57M-$12.82M-$12.18M—
Shares outstanding————11.32M
Cash flow statement
Operating cash flow-$12.44M-$9.13M$5.24M-$13.53M-$2.18M
Capital expenditure—$15.00M$5.00M$20.00M—
Free cash flow—-$24.13M$240,000-$33.53M—
Investing cash flow—-$15.00M-$5.00M-$20.00M-$10.00M
Financing cash flow$16.23M$16.99M-$4.80M$16.46M$53.02M
Depreciation & amortization————$0
Stock-based compensation$6.29M$6.10M$2.61M$4.42M$2.47M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.